quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Is This the Right Time to Rebalance Your Portfolio?

View original at nasdaq.com
Is This the Right Time to Rebalance Your Portfolio? Key Points Some investors think it’s prudent to prune their top stocks in a bull market…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Everybody in the world is a long-term investor until the market goes down

    60% confidence
  • Amazon accounts for over 10% of his portfolio

    60% confidence
  • Believes in letting the winners ride instead of selling them too early for the sake of diversification

    60% confidence
  • Has been invested in stocks for nearly two decades and has never regularly rebalanced portfolio

    60% confidence
  • Does not plan to prune top stocks anytime soon

    60% confidence
  • AI could create the world's first trillionaire

    60% confidence
  • Stock Advisor analyst team identified 10 best stocks for investors to buy now, and Nvidia was not one of them

    60% confidence
  • There is a little-known company called an 'Indispensable Monopoly' providing critical technology both Nvidia and Intel need

    60% confidence

Data points we hold from this source

S&P 500 · total return199 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Is This the Right Time to Rebalance Your Portfolio? — Source | Via News | pt.VIA.NEWS